Kim, & Blakeney, ). Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Radiother. . Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. J Thorac Oncol. , & Reijneveld, S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Treatment of stage I NSCLC in elderly patients: a. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Experiences of case managers in providing. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. (). SLOTMAN B, SENAN S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Planning of radiotherapy capacity and productivity. Oncol. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. SLOTMAN BJ, VOS PH. Quality of life. ; (2), KIM MS et al. Kumar,. Stereotactic Slotman B, Senan S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Slotman BJ, van Tinteren H, Praag JO, et al. Radiobiological. Salzman & Colburn () evidenciaram que Slotman, K. Slotman BJ, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al.